Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5670d XBB.1.5 booster vaccine phase III comparison study
jRCT2031230424Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of duvofameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Geometric mean titer of neutralizing antibodies against SARS-CoV-2 Omicron XBB.1.5 at 4 weeks and Seroresponse rate of neutralizing antibodies against SARS-CoV-2 Omicron XBB.1.5 at 4 weeks. Started Jan 2024; status: completed.
02
Drugs
duvofameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230424.